Next Article in Journal
Under Pressure: Mechanical Stress Management in the Nucleus
Next Article in Special Issue
Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis
Previous Article in Journal
The Hagfish Gland Thread Cell: A Fiber-Producing Cell Involved in Predator Defense
Previous Article in Special Issue
The Regulation of Cellular Responses to Mechanical Cues by Rho GTPases
Article Menu

Export Article

Open AccessReview
Cells 2016, 5(2), 26; doi:10.3390/cells5020026

Structural Mechanisms and Drug Discovery Prospects of Rho GTPases

Department of Biochemistry, University of Alberta, Edmonton, AB, T6G 2H7, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Bor Luen Tang
Received: 12 April 2016 / Revised: 28 May 2016 / Accepted: 7 June 2016 / Published: 13 June 2016
(This article belongs to the Special Issue Regulation and Function of Small GTPases)
View Full-Text   |   Download PDF [884 KB, uploaded 13 June 2016]   |  

Abstract

Rho GTPases regulate cellular morphology and dynamics, and some are key drivers of cancer progression. This superfamily offers attractive potential targets for therapeutic intervention, with RhoA, Rac1 and Cdc42 being prime examples. The challenges in developing agents that act on these signaling enzymes include the lack of obvious druggable pockets and their membrane-bound activities. However, progress in targeting the similar Ras protein is illuminating new strategies for specifically inhibiting oncogenic GTPases. The structures of multiple signaling and regulatory states of Rho proteins have been determined, and the post-translational modifications including acylation and phosphorylation points have been mapped and their functional effects examined. The development of inhibitors to probe the significance of overexpression and mutational hyperactivation of these GTPases underscores their importance in cancer progression. The ability to integrate in silico, in vitro, and in vivo investigations of drug-like molecules indicates the growing tractability of GTPase systems for lead optimization. Although no Rho-targeted drug molecules have yet been clinically approved, this family is clearly showing increasing promise for the development of precision medicine and combination cancer therapies. View Full-Text
Keywords: cancer therapy; signal transduction; GTPase; Rho; RhoA; Rac1; Cdc42; GEF cancer therapy; signal transduction; GTPase; Rho; RhoA; Rac1; Cdc42; GEF
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Smithers, C.C.; Overduin, M. Structural Mechanisms and Drug Discovery Prospects of Rho GTPases. Cells 2016, 5, 26.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top